Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Chidambaram
Chidambaram Gunanathan, Tamil Nadu IN
| Patent application number | Description | Published |
|---|---|---|
| 20090112005 | PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES - The present invention provides a process for preparing amides, by reacting a primary amine and a primary alcohol in the presence of a Ruthenium catalyst, to generate the amide and molecular hydrogen. According to the process of the invention, primary amines are directly acylated by equimolar amounts of alcohols to produce amides and molecular hydrogen (the only byproduct) in high yields and high turnover numbers. This reaction is catalyzed by a Ruthenium complex, which is preferably based on a dearomatized PNN-type ligand of formula A1 or precursors thereof of formulae A2 or A3. Use of diamines in the reaction leads to bis-amides, whereas with a mixed primary/secondary amine substrate, chemoselective acylation of the primary amine group occurs. | 04-30-2009 |
Chidambaram Gunanathan, Rehovot IL
| Patent application number | Description | Published |
|---|---|---|
| 20110152525 | PROCESS FOR PREPARING AMINES FROM ALCOHOLS AND AMMONIA - The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands. | 06-23-2011 |
Chidambaram Jeyabalan, Broomfield, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20100175010 | Graphical Configuration and Management of Interfaces - System, methods, and computer program products are provided for creating, managing, and configuring interfaces and communications profiles of systems or networks. The system may receive input placing a first graphical image (associated with a communications profile) on a pane, receive input defining one or more of the attributes and/or parameters of the communications profile, and create or configure an interface in accordance with the communications profile. | 07-08-2010 |
Chidambaram Nachiappan, Sandy, UT US
| Patent application number | Description | Published |
|---|---|---|
| 20110312927 | Progesterone Containing Oral Dosage Forms and Related Methods - The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10 | 12-22-2011 |
| 20110312928 | Progesterone Containing Oral Dosage Forms and Related Methods - The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1. | 12-22-2011 |
Chidambaram Rameshkumar, Maharashtra IN
| Patent application number | Description | Published |
|---|---|---|
| 20090131678 | Novel reusable transition metal complex catalyst useful for the preparation of high pure quality 3,3'-diaminobenzidine and its analogues and a process thereof - The present invention provides a reusable transition metal complex catalyst useful for the preparation of high pure quality 3,3′-diaminobenzidine and its analogues. The present invention also provides to a process for the preparation of a reusable transition metal complex catalyst. The present invention further provides a process for the preparation of 3,3′-diaminobenzidine (DAB) or 3,3′,4,4′ Tetraminobiphenyl (TAB) using reusable transition metal complex catalyst. The high quality 3,3′-diaminobenzedine (DAB) and its analogues are prepared by coupling 4-halo-2-nitroaniline to 3,3′-dinitrobenzidine (DNB) using transition metals as catalysts followed by reduction of 3,3′-dinitrobenzidine to the corresponding substituted 3,3′-diaminobenzidine of formula 1 in high yields. | 05-21-2009 |